David Gee

David is CEO of TTP Ventures and manages our investments in Pulmagen Therapeutics and TeraView. David was also a director of Oxford Diffraction, which was acquired by Varian Inc in April 2008.

David has over 20 years' experience in business development, technology exploitation and venture capital. He began his industrial career at International Automotive Design and subsequently worked at Scientific Generics and ADL.

He has a PhD in Theoretical Physics and three years' research experience in high performance computing.